NSE IPO - Apply Online, Check Issue Date, Price, Lot Size & Allotment Status

Apply for NSE IPO:

Skip to main content

Live Aclaris Therapeutics, Inc. Share Price Chart

O H L

Aclaris Therapeutics, Inc. Performance Overview

Days Range
$5.40Low
$5.52High

Markets Today

Previous Close$5.40
Open$5.40
Volume326,047
Day's Range$5.40 - $5.52
52W Range$1.74 - $6.60
Market Cap$783.10 M

Historical Performance

1M Returns-14.35
3M Returns+20.00
6M Returns+47.54
1Y Returns+176.92
5Y Returns-70.26
10Y Returns-77.31

Aclaris Therapeutics, Inc. Fundamentals

Market Cap$783.10 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$7.83 M
ROE TTM-0.50
EPS TTM$-0.59
Quarterly Earnings Growth YOYN/A
PB Ratio5.97
EBITDA$-73.62 M
Profit Margin-829.58
Market Cap$783.10 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$7.83 M
ROE TTM-0.50
EPS TTM$-0.59
Quarterly Earnings Growth YOYN/A
PB Ratio5.97
EBITDA$-73.62 M
Profit Margin-829.58

Aclaris Therapeutics, Inc. Profit & Loss

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Revenue +$1.46 M$1.78 M$3.30 M$1.29 M$2.00 M$1.63 M
Gross Profit +$949.00 K$1.26 M$2.76 M$763.00 K$1.60 M$1.41 M
Operating Income -$17.78 M-$18.41 M-$17.15 M-$22.73 M-$22.19 M-$24.24 M
EBITDA -$17.66 M-$18.29 M-$16.94 M-$22.23 M-$22.09 M-$24.13 M
Interest Expense $0$0$0$0$0$0
Depreciation $128.00 K$114.00 K$210.00 K$502.00 K$102.00 K$107.00 K
Income Before Tax -$15.09 M-$15.43 M-$14.61 M-$19.80 M-$19.82 M-$21.50 M
Income Tax Expense $0$0$0$0$0$0
Net Income +-$15.09 M-$15.43 M-$14.61 M-$19.80 M-$19.82 M-$21.50 M
Net Profit Margin -1036.77%-868.26%-442.98%-1528.57%-993.19%-1320.14%

Aclaris Therapeutics, Inc. Financials Balance Sheet In USD

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Share Capital $1.00 K$1.00 K$1.00 K$1.00 K$1.00 K$1.00 K
Reserve & Surplus -$917.51 M-$932.89 M-$947.39 M-$967.17 M-$987.59 M-$1.01 B
Non-Current Liabilities $32.51 M$30.57 M$29.80 M$28.73 M$27.70 M$26.87 M
Current Liabilities $21.51 M$26.84 M$25.63 M$28.64 M$27.37 M$28.24 M
Total Liabilities $54.03 M$57.41 M$55.43 M$57.38 M$55.07 M$55.11 M
Fixed Assets $942.00 K$868.00 K$811.00 K$761.00 K$750.00 K$664.00 K
Current Assets $108.79 M$104.20 M$100.59 M$96.32 M$110.23 M$97.77 M
Total Assets $198.09 M$189.15 M$175.53 M$160.46 M$198.72 M$179.69 M

Aclaris Therapeutics, Inc. Cash Flow

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Net Income -$15.09 M-$15.43 M-$14.61 M-$19.80 M-$19.82 M-$21.50 M
Operating Cash Flow -$13.06 M-$9.99 M-$10.93 M-$13.13 M-$18.15 M-$19.85 M
Investing Cash Flow $19.12 M$5.05 M$13.83 M$10.37 M-$30.93 M$10.26 M
Financing Cash Flow -$275.00 K-$9.00 K-$3.04 M-$2.53 M$57.78 M$91.00 K
Change in Cash $5.79 M-$4.96 M-$146.00 K-$5.30 M$8.70 M-$9.49 M

Aclaris Therapeutics, Inc. Return Calculator

The Aclaris Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$3,018
Invested Amount$10,000
Est. Returns$-6,982
Invest in USA Stock Today

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

FAQs

Aclaris Therapeutics, Inc. (ACRS) share price as of September 18, 2026 is $5.48. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Aclaris Therapeutics, Inc. (ACRS) Share by opening an international trading account with Angel One.
Purchasing Aclaris Therapeutics, Inc. (ACRS) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Aclaris Therapeutics, Inc. (ACRS) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Aclaris Therapeutics, Inc. (ACRS) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Aclaris Therapeutics, Inc. on September 18, 2026, is $783.10 M.
Aclaris Therapeutics, Inc. operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Aclaris Therapeutics, Inc. (ACRS) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.

Diversify Your Portfolio with US Stocks

Invest in Wall Street Giants from India

+91
Top US Stocks

VIEW ALL

Open Free Demat Account!

Join our 3.8 Cr+ happy customers
+91